[225Ac]-FPI-2059 — Investigational Agent
Radiopharmaceutical · Phase 1 · Fusion Pharmaceuticals
Mechanism of Action
[225Ac]-FPI-2059 is a small-molecule targeted alpha therapy delivering actinium-225 to neurotensin receptor 1 (NTSR1)-expressing tumors. Emitted alpha particles cause high-energy, short-range DNA double-strand breaks in receptor-positive malignant cells.
Investigational Indications
- NTSR1-expressing advanced solid tumors
- Pancreatic ductal adenocarcinoma
- Head and neck squamous cell carcinoma
- Colorectal cancer